Medlive Technology Co., Ltd. released its Monthly Return for the period ended 31 August 2026, showing no alterations to either its authorised or issued share capital and confirming compliance with Hong Kong’s public-float requirements.
Authorised / Registered Capital • Authorised share capital stood unchanged at 50.00 billion ordinary shares with a par value of USD 0.00001 each, representing total authorised capital of USD 0.50 million.
Issued and Treasury Shares • Issued shares (excluding treasury shares) remained at 740.27 million. • The company held no treasury shares at month-end, identical to the prior month. • No share issuances, cancellations, repurchases, or transfers occurred during August.
Public Float Compliance • Medlive affirmed that it continued to satisfy the Hong Kong Main Board’s minimum public-float threshold of 24.98 % as at 31 August 2026.
Equity Incentive Plans • Under the Post-IPO Share Option Scheme adopted on 18 June 2021, there were no outstanding options and no options exercised during the month. • The scheme still permits the future issuance of up to 69.02 million shares.
Other Securities • The company reported no outstanding warrants, convertible securities, or other equity-linked instruments, and no additional arrangements to issue shares.
Governance Confirmation • The Board, represented by Company Secretary Yang Yanling, confirmed that all regulatory and listing rule requirements were observed for the period under review.
The unchanged capital structure and continued adherence to public-float mandates signal operational stability for Medlive as of the end of August 2026.
Comments